Navigation Links
Mastix Medica Introduces RenaGum™ - The First Medical Food Chewing Gum
Date:8/8/2013

Hunt Valley, MD (PRWEB) August 08, 2013

Mastix Medica, an innovative specialty manufacturer of dietary supplements and functional foods, has introduced RenaGum™, a novel medical food that helps patients with chronic kidney disease (CKD) maintain normal phosphate levels. RenaGum™ is specially formulated with chitosan, a well-known dietary, medical and environmental binding agent. Clinical studies show that chitosan released from chewing gum is an effective way to help maintain normal serum phosphate levels in CKD patients. RenaGum™ is made using natural ingredients, a non-allergenic chitosan from a vegetable source, not from shellfish, and is also Kosher certified. As a medical food product, RenaGum™ needs to be used under the supervision of a physician.

CKD is a growing health problem in the United States, with at least 20 million people in various stages of CKD including about 500,000 people with end-stage renal disease (ESRD) requiring hemodialysis. The two main causes of CKD are diabetes and high blood pressure accounting for up to 2/3 of all CKD cases. In people with CKD, and especially people with ESRD, one of the most important co-existing disorders is caused by increased levels of phosphorus (hyperphosphatemia) in the body.

Elevated serum phosphate levels are significantly associated with cardiovascular calcification and increased cardiac mortality. People with CKD and ESRD need to watch what they eat and drink and may take phosphate binder drugs that their doctor prescribes. These phosphate binder drugs are taken by patients during meals to prevent the absorption of phosphate in the digestive system from the food that is consumed.

“We are excited that Mastix Medica is introducing its first proprietary product, RenaGum™, to help people with CKD and ESRD maintain healthy phosphate levels,” commented Robert Estey, CEO of Mastix Medica. “RenaGum™ is a complimentary medical food that is chewed after a meal. It is designed to work with and complement a patient’s prescribed binder drugs at a different time and in a different way,” he continued. “RenaGum™ is not a replacement for a patient’s prescribed binder drugs. When the gum is chewed, the chitosan combines with phosphate found in saliva and then in the digestive tract after the saliva is swallowed,” Estey stated. “We expect RenaGum™ to become an integral component of the dietary management of kidney disease in patients with CKD and ESRD. Patients also like RenaGum™ because, as a chewing gum, it does not add to the heavy pill burden they already take with their meals,” concluded Mr. Estey.

More information about RenaGum™ can be found at http://www.renagum.com.

About Medical Foods
A Medical Food is an FDA-regulated product defined by Congress as part of the Orphan Drug Act. A Medical Food is specially formulated to be administered orally under the supervision of a physician and is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation. Medical Foods have clinical studies supporting their use for specific conditions due to nutritional imbalances or deficiencies. Medical Foods are made with ingredients that are Generally Recognized As Safe (GRAS), the highest FDA standard of safety given to foods.

About Mastix Medica
Mastix Medica is a specialty manufacturer with expertise in unique tableted dosage forms like tableted chewing gum, lozenges and chewable tablets. Mastix Medica has a proprietary tableted gum manufacturing process that is unique in the industry. With a history in candy manufacturing, Mastix Medica has broad custom product development capabilities that have expanded into functional foods and dietary supplements, with particular expertise in hard to formulate tablet products, direct compression chewing gum and taste masking.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11010469.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. California Physical Therapy Association Strongly Supports the "Promoting Integrity in Medicare Act" to Fight Self-Referral of Physical Therapist Services
2. China Medical Flat Panel Detector Market & Pressure Injector 2013 Research Reports Now Available at ReportsnReports.com
3. Global Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline: MarketResearchReports.Biz
4. Emerging Global Leader in Emergency Thermotherapy for Traumatic Brain Injury Expands US Operations to Site on the Campus of New York Medical College
5. Top Drug Testing Kit Distributor, Medical Disposables Corp. Joins the Florida Staffing Association
6. National Reference Laboratory, Warde Medical Laboratory to Showcase at 2013 AACC Clinical Lab Expo
7. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
8. Saladax Biomedical Announces Addition to Leadership Team
9. Medical Device and Drug Research, New Life Science Webinar Hosted by Xtalks
10. Medical Power Supply Market Worth $866.8 Million By 2017
11. Tutela Launches Genesis II - Next Generation Wireless Medical Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
(Date:2/8/2016)... Should antibiotic bone cement products be used ... infection after standard total hip or knee replacement surgery? ... have been fielding a lot lately. "Antibiotic ... --> "Antibiotic Bone Cement: Fighting ... --> While there isn,t a simple answer, ECRI ...
(Date:2/8/2016)... , February 8, 2016 ... Oncology Private Limited, an innovation-driven oncology company developing ... and less toxic, today announced that chairman emeritus ... has invested in the company as part of ... round, joining existing investors Navam Capital and Aarin ...
(Date:2/8/2016)... ... 2016 , ... Thomas J. Todorow has joined the University ... Corporate Services and the Chief Financial Officer at The Children’s Hospital of Philadelphia ... Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP and The ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter ... up 1,187% compared with fourth quarter of 2014. Gross margin ... (loss: 30.0). Earnings per share increased to SEK 6.39 (loss: ... (neg: 74.7). , --> --> ... 2,900.5 M (233.6), up 1,142% compared with 2014. Gross margin ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
Breaking Biology News(10 mins):